Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis

Comparative Study of Efficacy and Adverse Effects of Ginger Extract and Loratadine for Treatment of Allergic Rhinitis Patients (Clinical Trial Phase II)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02576808

Enrollment

Registered

2015-10-15

Start date

2015-10-31

Completion date

2017-10-31

Last updated

2017-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinitis,Allergic

Brief summary

Efficacy and adverse effects of Ginger extract in treating allergic rhinitis patients compared with Loratadine.The double blind randomized controlled trial study was approved by the Human Research Ethics Committee of Thammasat University NO.1.

Detailed description

The double blind randomized controlled trial study. Patients who meet the inclusion criteria and do not fall into any exclusion criteria will be randomly placed into the experimental group, who will receive ginger extract capsules, or the control group, who will receive loratadine for 42 days.

Interventions

DRUGGinger extract

Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days

DRUGLoratadine

Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Patients have moderate allergic rhinitis (itching and nasal obstruction, watery nasal discharge, sneezing and congestion )with a minimum total nasal symptom score 7 point 2. These patients do not have the respiratory disease such as tuberculosis, nasal polyps. 3. These patients do not have the history of disease: heart disease, kidney disease, liver disease, epilepsy, high blood pressure and severe asthma. 4. These patients are not pregnant or breastfeeding. 5. These patients have normal BMI and vital signs.

Exclusion criteria

1. Those who have taken anti-coagulant and anti-platelet aggregation medications. 2. Those who get serious side effects from Loratadine and ginger allergy. 3. Communication problems especially listening and interview.

Design outcomes

Primary

Measure	Time frame	Description
Nasal symptom	42days	Nasal symptom from Total nasal symptom score

Secondary

Measure	Time frame	Description
Quality of Life	42days	Quality of Life from Rhinoconjunctivitis Quality of Life Questionnaire
Nasal patency	42days	Nasal patency from Acoustic rhinometry

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026